Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MediTrust Completes $308 Million Funding for China Healthcare Services Platform

publication date: Aug 19, 2021

Shanghai MediTrust Health Technology completed a $308 million Series C funding to support its China healthcare services platform. Established in 2017, MediTrust claims to be China's leading private healthcare payer using its proprietary platforms for both healthcare and insurance companies. The company seeks to provide high-quality services that help lower medical costs. Care2Pay, a healthcare benefit platform, collaborates with more than 50 pharmas and insurers and over 2,000 Direct-to-Patient China pharmacies. It provides access to novel drugs at a lower price. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital